Cargando…

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy

Detalles Bibliográficos
Autores principales:	Dal Collo, Giada, Takam Kamga, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526481/ https://www.ncbi.nlm.nih.gov/pubmed/37760473 http://dx.doi.org/10.3390/cancers15184503

Ejemplares similares

Editorial: Influence of potential diagnostic biomarkers in lung cancer
por: Takam Kamga, Paul
Publicado: (2023)

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
por: Costantini, Adrien, et al.
Publicado: (2019)

Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2019)

Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway
por: Kamga, Paul Takam, et al.
Publicado: (2018)

The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche
por: Takam Kamga, Paul, et al.
Publicado: (2021)

Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2020)

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
por: Matsuo, Norikazu, et al.
Publicado: (2019)

Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
por: Costantini, Adrien, et al.
Publicado: (2020)

A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Li, Siqi, et al.
Publicado: (2020)

Host histone acetylation unlocks HDAC inhibitor potential
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Evolving cardiac biomarkers for immune checkpoint inhibitor related myocarditis in cancer patients
por: Talukder, Suprateeka, et al.
Publicado: (2023)

Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives
por: Yang, Changjiang, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers
por: Pichler, Renate
Publicado: (2020)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer
por: Mehlman, Camille, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
por: Baxevanis, Constantin N.
Publicado: (2023)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells
por: Bazzoni, Riccardo, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
por: Giroux Leprieur, Etienne, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Unlocking the full potential of probiotics: refocusing on microbial demands
por: Joossens, Marie
Publicado: (2020)

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
por: Liu, Delong
Publicado: (2019)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy
por: Murakata, Yoshiko, et al.
Publicado: (2022)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis
por: Moquin-Beaudry, Gaël, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_srulmd06o5ufaru4d4d1bf8d4v